536 filings
8-K
COCP
Cocrystal Pharma Inc
1 May 24
Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza
8:00am
PRE 14A
COCP
Cocrystal Pharma Inc
Preliminary proxy
26 Apr 24
5:12pm
10-K/A
2023 FY
COCP
Cocrystal Pharma Inc
Annual report (amended)
17 Apr 24
5:00pm
10-K
2023 FY
COCP
Cocrystal Pharma Inc
Annual report
28 Mar 24
8:01am
8-K
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
g05wep td0gt
19 Mar 24
Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A
8:30am
8-K
sjyp6627mjdna98xdk
1 Mar 24
Termination of a Material Definitive Agreement
4:15pm
8-K
vkvx 8xp8
8 Jan 24
Regulation FD Disclosure
8:00am
8-K
qfgrhq62aveg8i
4 Jan 24
Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates
4:01pm
SC 13G/A
9qmenow8 odp
2 Jan 24
Cocrystal Pharma / SABBY MANAGEMENT ownership change
9:53am
8-K
eqabksn
21 Dec 23
Termination of a Material Definitive Agreement
5:00pm
8-K
xa8pw7g471 b58sh2a
6 Dec 23
Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A
8:00am
8-K
lq7dn3
4 Dec 23
Regulation FD Disclosure
8:00am
8-K
ro5r6x
29 Nov 23
Regulation FD Disclosure
8:00am
8-K
mh6 pfatncspj
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
3jdsp nph3vu
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
d6vtup3k72gn9u6
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
4
ms096u2n j1el
20 Jul 23
Cocrystal Pharma / PHILLIP MD ET AL FROST ownership change
4:05pm